Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
DNTH Stock Chart & Stats
$55.19
$0.37(1.44%)
At close: 4:00 PM EST
$55.19
$0.37(1.44%)
Day’s Range― - ―
52-Week Range$13.37 - $57.50
Previous CloseN/A
Volume29.07K
Average Volume (3M)1.00M
Market Cap
$2.39B
Enterprise Value$1.94B
Total Cash (Recent Filing)$402.61M
Total Debt (Recent Filing)$1.28M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 19, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding43,223,090
10 Day Avg. Volume588,847
30 Day Avg. Volume1,003,841
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.06
Price to Sales (P/S)116.48
P/FCF Ratio-9.28
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue631.52
Enterprise Value/Gross Profit631.52
Enterprise Value/Ebitda-14.25
Forecast
1Y Price Target
$83.40Price Target Upside51.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.74
Revenue Forecast (FY)$1.75M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy EvidencePositive placebo-controlled results in generalized myasthenia gravis demonstrate that claseprubart can markedly reduce symptoms in autoimmune neuromuscular disease, supporting strong prescriber and patient uptake potential.
Pipeline And Commercial ExpansionAcquisition of DNTH212 combined with ongoing MoMeNtum efforts and rapid trial enrollment broadens the company’s pipeline and highlights an underappreciated commercial opportunity in multifocal motor neuropathy.
Pivotal Clinical CatalystAn interim responder analysis from the open‑label portion of the CAPTIVATE study serves as a clear go/no‑go clinical catalyst that could validate claseprubart's activity in chronic inflammatory demyelinating polyneuropathy and materially de‑risk the program.
Bears Say
Analyst Independence RiskA research firm’s business relationship with covered companies can create perceived conflicts of interest that undermine confidence in analyst reports and diminish investor trust.
Data Risk From Interim AnalysisReliance on an interim responder readout from an open‑label study risks ambiguous or non‑definitive findings that may not translate into regulatory approval or broad commercial uptake.
Safety And Regulatory UncertaintyLingering theoretical concerns about antinuclear antibodies and autoimmune risk could prompt added safety monitoring or regulatory questions, slowing clinical adoption until further safety data are available.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $13.37 and its highest was $57.50 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $2.39B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 17 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.867 by -$0.103.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -1.08.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 43,223,090 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.867. Following the earnings report the stock price went up 8.005%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.40 (51.11% Upside)
$83.40 (51.11% Upside)
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.18%
12-Months-Change
Fundamentals
Return on Equity
-28.57%
Trailing 12-Months
Asset Growth
-11.62%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$83.40
▲(51.11% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
<0.01% Insiders
20.77% Mutual Funds
11.70% Other Institutional Investors
57.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---